Oruka Therapeutics, Inc. - Asset Resilience Ratio
Oruka Therapeutics, Inc. (ORKA) has an Asset Resilience Ratio of 50.64% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Oruka Therapeutics, Inc. (ORKA) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2024)
This chart shows how Oruka Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. See Oruka Therapeutics, Inc. (ORKA) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Oruka Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Oruka Therapeutics, Inc. market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $257.90 Million | 50.64% |
| Total Liquid Assets | $257.90 Million | 50.64% |
Asset Resilience Insights
- Very High Liquidity: Oruka Therapeutics, Inc. maintains exceptional liquid asset reserves at 50.64% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Oruka Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare Oruka Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Oruka Therapeutics, Inc. (2005–2024)
The table below shows the annual Asset Resilience Ratio data for Oruka Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 79.31% | $314.07 Million | $396.02 Million | +54.64pp |
| 2017-12-31 | 24.67% | $3.05 Million | $12.37 Million | -31.21pp |
| 2016-12-31 | 55.88% | $13.76 Million | $24.63 Million | +1.60pp |
| 2007-12-31 | 54.28% | $65.51 Million | $120.68 Million | +3.96pp |
| 2006-12-31 | 50.32% | $92.79 Million | $184.41 Million | +20.17pp |
| 2005-12-31 | 30.15% | $32.57 Million | $108.05 Million | -- |
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-1… Read more